Core Insights - Eyes On Park has introduced the Envision by InMode system, a revolutionary non-invasive technology for advanced dry eye treatment in New York City [1][4][17] - The system combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, improving patient outcomes significantly [3][16] Treatment Technology - The Envision system utilizes two complementary technologies: Forma-I radiofrequency technology and Lumecca-I intense pulsed light therapy [5][7] - Forma-I delivers bipolar radiofrequency energy to enhance blood circulation and stimulate natural healing processes, particularly effective for meibomian gland dysfunction [6][11] - Lumecca-I uses intense pulsed light to reduce inflammation and improve symptoms in patients with inflammatory dry eye and ocular rosacea [7][12] Treatment Benefits - Patients typically experience noticeable improvement after just one session, with optimal results achieved after a series of treatments [15][16] - The Envision system provides a non-invasive treatment option that requires no downtime, allowing patients to resume normal activities immediately [15][16] Personalized Care - Treatment plans are customized based on comprehensive diagnostic testing, including advanced K5M diagnostic scans, allowing for tailored approaches to each patient's specific needs [14][15] - The practice emphasizes that no two cases of dry eye disease are identical, leading to higher patient satisfaction through targeted treatment [15] Availability - The Envision by InMode system is now available at Eyes On Park, and patients can schedule consultations to determine the suitability of this advanced treatment [17][18]

INMODE PROFILE & STRATEGY APRIL 2025 SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "exp ...

InMode (INMD) Q1 2025 Earnings Call April 28, 2025 08:30 AM ET Company Participants Miri Segal - Founder & CEOMoshe Mizrahy - Chairman and Chief Executive OfficerYair Malca - CFOMatt Taylor - Managing DirectorCaitlin Cronin - DirectorSam Eiber - Vice President - Equity ResearchDane Reinhardt - Senior Equity Research Associate Conference Call Participants Matt Miksic - Equity Research AnalystDanielle Antalffy - AnalystMike Matson - Senior Equity Research Analyst Operator Good day and welcome to InMode's Firs ...

This quarterly report represents an earnings surprise of -6.06%. A quarter ago, it was expected that this maker of cosmetic surgery devices would post earnings of $0.50 per share when it actually produced earnings of $0.42, delivering a surprise of -16%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. InMode, which belongs to the Zacks Medical - Products industry, posted revenues of $77.87 million for the quarter ended March 2025, surpassing the Zacks Consensus Esti ...

InMode (INMD) Q1 2025 Earnings Call April 28, 2025 08:30 AM ET Company Participants Miri Segal - Founder & CEOMoshe Mizrahy - Chairman and Chief Executive OfficerYair Malca - CFOMatt Taylor - Managing DirectorCaitlin Cronin - DirectorSam Eiber - Vice President - Equity ResearchDane Reinhardt - Senior Equity Research Associate Conference Call Participants Matt Miksic - Equity Research AnalystDanielle Antalffy - AnalystMike Matson - Senior Equity Research Analyst Operator Good day and welcome to InMode's Firs ...

In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: U.S. GAAP Results (U.S. dollars in thousands, except for per share data) | | Q1 2025 | Q1 2024 | | --- | --- | --- | | Revenues | $77,874 | $80,284 | | Gross ...

Core Viewpoint - InMode Ltd. is set to release its financial results for the first quarter of 2025 on April 28, 2025, with preliminary revenue expectations ranging from $77.2 million to $77.5 million and a projected non-GAAP gross margin of 78% to 79% [6][2]. Financial Results - The company anticipates first quarter 2025 revenue to be between $77.2 million and $77.5 million [6]. - The projected non-GAAP gross margin for the same period is expected to be in the range of 78% to 79% [6]. - For the full year 2025, InMode expects revenue to be between $395 million and $405 million [6]. Conference Call Details - A conference call to discuss the first quarter 2025 financial results will take place on April 28, 2025, at 8:30 a.m. Eastern Daylight Time [3]. - Key management personnel, including the CEO, CFO, and CTO, will present during the call [3]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [4]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology [6][7]. - The company aims to enhance surgical procedures and improve existing treatments across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [6][7].

InMode (INMD) shares ended the last trading session 6.8% higher at $15.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 23% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.45 per share in its upcoming ...

Just over a year ago, I wrote my first article about InMode (NASDAQ: INMD ), where I recommended the shares as a Hold due to management’s inefficient capital allocation. If you haven't seen it, I recommendMy name is Guilherme Nunes, and I am a certified stock analyst in Brazil with over 10 years of experience analyzing and publishing reports on companies in Brazil, Chile, and the United States.Throughout my career, I’ve focused primarily on small-cap companies, applying a deep value investment approach. Cur ...

YOKNEAM, Israel, March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 2:15 pm Eastern Time on Tuesday, April 8, and a live webcast of the presentation can be accessed ...